HK1195512A1 - Polysaccharide protein conjugate vaccines - Google Patents
Polysaccharide protein conjugate vaccinesInfo
- Publication number
- HK1195512A1 HK1195512A1 HK14109137.9A HK14109137A HK1195512A1 HK 1195512 A1 HK1195512 A1 HK 1195512A1 HK 14109137 A HK14109137 A HK 14109137A HK 1195512 A1 HK1195512 A1 HK 1195512A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- protein conjugate
- conjugate vaccines
- polysaccharide protein
- polysaccharide
- vaccines
- Prior art date
Links
- 108010060123 Conjugate Vaccines Proteins 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 229920001282 polysaccharide Polymers 0.000 title 1
- 239000005017 polysaccharide Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49338903P | 2003-08-06 | 2003-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1195512A1 true HK1195512A1 (en) | 2014-11-14 |
Family
ID=34135243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14109137.9A HK1195512A1 (en) | 2003-08-06 | 2014-09-10 | Polysaccharide protein conjugate vaccines |
Country Status (9)
Country | Link |
---|---|
US (1) | US9173931B2 (en) |
EP (4) | EP2366403B1 (en) |
CN (4) | CN100423774C (en) |
AU (2) | AU2004281630A1 (en) |
BR (2) | BRPI0413323B8 (en) |
CA (4) | CA2535043A1 (en) |
HK (1) | HK1195512A1 (en) |
WO (2) | WO2005014037A2 (en) |
ZA (2) | ZA200601688B (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048432B2 (en) | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
WO2005014037A2 (en) | 2003-08-06 | 2005-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
JP5718545B2 (en) * | 2004-04-30 | 2015-05-13 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Neisseria meningitidis conjugate vaccination |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
AU2005249571B9 (en) * | 2004-06-04 | 2011-01-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for preparing immunogenic conjugates |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
PT1868645E (en) | 2005-04-08 | 2012-05-17 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CA2612980C (en) * | 2005-06-27 | 2019-01-15 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising a haemophilus influenzae type b saccharide conjugate |
KR101711903B1 (en) * | 2006-03-17 | 2017-03-03 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | Methods for preparing complex multivalent immunogenic conjugates |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
EP2043692B1 (en) | 2006-07-25 | 2016-05-18 | Lipoxen Technologies Limited | Polysaccharide derivatives of erythropoietin |
US8003112B2 (en) | 2009-04-16 | 2011-08-23 | Howard University | Meningococcal and pneumococcal conjugate vaccine and method of using same |
BR112012009014B8 (en) * | 2009-09-30 | 2022-10-04 | Novartis Ag | PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION |
ES2707778T3 (en) | 2009-12-30 | 2019-04-05 | Glaxosmithkline Biologicals Sa | Immunogens polysaccharides conjugated with carrier proteins of E. coli |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
CN102526724B (en) * | 2011-01-14 | 2015-07-22 | 四川大学 | Aluminum hydroxide gel-polysaccharide composite immunologic adjuvant and preparation method and application thereof |
CN104428008B (en) | 2012-05-24 | 2020-10-09 | 美国政府(由卫生和人类服务部的部长所代表) | Multivalent meningococcal conjugates and methods of making conjugates |
EP2724730A1 (en) | 2012-10-29 | 2014-04-30 | Institut Pasteur | Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri |
EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
US10105431B2 (en) | 2014-01-21 | 2018-10-23 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US10188739B2 (en) | 2014-02-27 | 2019-01-29 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
CN104198725B (en) * | 2014-08-14 | 2016-04-06 | 上海睿康生物科技有限公司 | Cyclic citrullinated peptid detection kit |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
PE20180460A1 (en) | 2015-06-08 | 2018-03-06 | Serum Inst Of India Private Ltd | METHODS TO IMPROVE THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND A MULTIVALENT VACCINE FORMULATION OBTAINED THROUGH THE SAME |
US20170333546A1 (en) * | 2015-12-08 | 2017-11-23 | Jl Medical Corporation | Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
PT3506935T (en) | 2016-09-02 | 2024-04-01 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CN111132691A (en) | 2017-06-10 | 2020-05-08 | 创赏有限公司 | Multivalent conjugate vaccines with divalent or multivalent conjugate polysaccharides providing improved immunogenicity and avidity |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
WO2019126197A1 (en) | 2017-12-18 | 2019-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacterial polysaccharide-conjugated carrier proteins and use thereof |
CN108525003A (en) * | 2018-03-13 | 2018-09-14 | 中山大学 | Based on the double cross of acylhydrazone key and hydrophobe self assembly connection hybridized hydrogel, preparation method and skin histology wound repair agent |
CN108498847A (en) * | 2018-03-13 | 2018-09-07 | 中山大学 | Macromolecule hydrogel, preparation method based on acylhydrazone key and skin histology adhesive |
CN109001198A (en) * | 2018-09-03 | 2018-12-14 | 艾美卫信生物药业(浙江)有限公司 | The method that the NaTDC precipitation method detect free polysaccharide in Hib combined vaccine |
CA3191005A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
CN113274489B (en) * | 2021-04-30 | 2023-08-29 | 山东省药学科学院 | Chitin oligosaccharide vaccine for preventing fungal infection and preparation method thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
DK163176C (en) * | 1985-09-27 | 1992-06-22 | Schweiz Serum & Impfinst | POISONOUS CONJUGATE VACCINE AGAINST INFECTIONS OF PSEUDOMONA'S AERUGINOSA AND ESCHERICHIA COLI BACTERIES, METHOD OF PRODUCING IT AND USING THE VACCINE |
JPS63295408A (en) * | 1987-05-28 | 1988-12-01 | Mitsubishi Gas Chem Co Inc | Method for purifying aqueous hydrazine hydrate solution |
US5066408A (en) * | 1990-03-15 | 1991-11-19 | Powell Jonathan S | Means and method to treat swimming pool water |
NZ239643A (en) * | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
US5480643A (en) * | 1991-10-16 | 1996-01-02 | Ecolab Inc. | Stable antimicrobial dialdehyde composition and methods of use |
US5849301A (en) * | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
WO1996029094A1 (en) * | 1995-03-22 | 1996-09-26 | Andrew Lees | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
US20020054884A1 (en) * | 1995-06-23 | 2002-05-09 | Smithkline Beecham Biologicals, Sa | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
AU4769701A (en) * | 2000-03-22 | 2001-10-03 | Solulink Inc | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
US20050014037A1 (en) * | 2002-12-04 | 2005-01-20 | Chris Boyer | Fuel cell with recombination catalyst |
WO2005014037A2 (en) | 2003-08-06 | 2005-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
-
2004
- 2004-08-06 WO PCT/US2004/025477 patent/WO2005014037A2/en active Application Filing
- 2004-08-06 WO PCT/US2004/026431 patent/WO2005037320A2/en active Application Filing
- 2004-08-06 CN CNB2004800289783A patent/CN100423774C/en not_active Expired - Fee Related
- 2004-08-06 EP EP10180020.9A patent/EP2366403B1/en not_active Expired - Lifetime
- 2004-08-06 AU AU2004281630A patent/AU2004281630A1/en not_active Abandoned
- 2004-08-06 US US10/566,898 patent/US9173931B2/en active Active
- 2004-08-06 AU AU2004263135A patent/AU2004263135B2/en not_active Expired
- 2004-08-06 CN CN2004800289779A patent/CN1863553B/en not_active Expired - Lifetime
- 2004-08-06 BR BRPI0413323A patent/BRPI0413323B8/en active Search and Examination
- 2004-08-06 CA CA002535043A patent/CA2535043A1/en not_active Abandoned
- 2004-08-06 CN CN2011100539687A patent/CN102151331B/en not_active Expired - Lifetime
- 2004-08-06 CA CA2948114A patent/CA2948114C/en not_active Expired - Lifetime
- 2004-08-06 CN CN201310439763.1A patent/CN103623405B/en not_active Expired - Lifetime
- 2004-08-06 EP EP04809568A patent/EP1651262A2/en not_active Withdrawn
- 2004-08-06 CA CA2844154A patent/CA2844154C/en not_active Expired - Lifetime
- 2004-08-06 EP EP10180008.4A patent/EP2366404B1/en not_active Expired - Lifetime
- 2004-08-06 BR BRPI0413309A patent/BRPI0413309B8/en active IP Right Grant
- 2004-08-06 CA CA2534870A patent/CA2534870C/en not_active Expired - Lifetime
- 2004-08-06 EP EP04786467.3A patent/EP1651261B1/en not_active Expired - Lifetime
-
2006
- 2006-02-27 ZA ZA200601688A patent/ZA200601688B/en unknown
- 2006-02-27 ZA ZA200601689A patent/ZA200601689B/en unknown
-
2014
- 2014-09-10 HK HK14109137.9A patent/HK1195512A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1195512A1 (en) | Polysaccharide protein conjugate vaccines | |
AU2003257003A8 (en) | Chimeric multivalent polysaccharide conjugate vaccines | |
HK1204574A1 (en) | Multivalent meningococcal derivatized polysaccharide protein conjugates and corresponding vaccines | |
HK1088529A1 (en) | Aseptic combination preparation | |
GB0329146D0 (en) | Vaccine | |
IL173921A0 (en) | Vaccine | |
SI1592457T1 (en) | Folate-vinblastine conjugate as medicament | |
GB0323840D0 (en) | Vaccines | |
EP1682572A4 (en) | Protein expression | |
GB0305794D0 (en) | Vaccine | |
EP1591451A4 (en) | Peptide conjugate | |
GB0330079D0 (en) | Vaccine | |
GB2420185B (en) | Ophthalmoscope | |
GB0321614D0 (en) | Vaccines | |
GB0304634D0 (en) | Vaccines | |
GB0317376D0 (en) | Immunogenic protein and uses thereof | |
GB0308691D0 (en) | Vaccine preparations | |
AU2003900767A0 (en) | Idiotypic vaccine | |
GB2407395B (en) | Ophthalmoscope | |
GB0330007D0 (en) | Vaccines | |
GB0306445D0 (en) | Conjugate | |
GB0329827D0 (en) | Vaccine | |
GB0305028D0 (en) | Vaccine | |
GB0326757D0 (en) | Vaccine | |
GB0304635D0 (en) | Vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20240801 |